Announced Tue, 16 Jun · 18:39 IST
Zydus completes USD 166.33 mn acquisition of US-listed Assertio Holdings
ZYDUSLIFE · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Price reaction · full curve 14 horizons · vs prior close
-0.5%1-day move
₹1079.80
prior close
₹1069.90
base price
After-mkt
timing
5m10m15m30m1D2D3D4D5D7D15D1M2M3M
-0.4+0.1+0.1+0.1-0.5-0.7+0.5+3.0+1.6+4.1+7.5+5.9——
Up moveDown movePending
AI summary
Zydus Lifesciences has completed the acquisition of Assertio Holdings Inc. (formerly Nasdaq: ASRT), a US specialty oncology pharma company, making it a wholly owned subsidiary. Deal priced at USD 23.50 per share in cash, totalling USD 166.33 million on a fully diluted basis. Assertio's key product ROLVEDON®, a USFDA-approved biologic for chemotherapy support, had CY2025 revenue of USD 68.23 million.
Likely market impact
Expands Zydus's US specialty oncology presence with an approved biologic and commercial infrastructure. All-cash deal, no equity dilution or related-party concerns.